IP Library Granted Patent US 9,902,937
Granted Patent B2
US 9,902,937 · App. 14/280,957 · Granted Feb 27, 2018

Methods for culturing minimally-passaged fibroblasts and uses thereof

Inventors: John Maslowski (Pottstown, PA); Myrna F. Thomas (Hainesport, NJ); Marie A. Lindner (Radnor, PA)
Assignee: Fibrocell Technologies, Inc.
C12N5/0656C12N2509/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,902,937
App. No.
14/280,957
Granted
Feb 27, 2018
Kind
B2
Abstract

The present invention relates to novel methods of growing at least 100 million minimally-passaged fibroblasts from a small biopsy specimen. The invention includes methods wherein a small biopsy specimen is seeded directly into a large tissue culture flask, and passaged no more than three times.

Claims (13)

1. A topical composition comprising fibroblast conditioned medium, wherein the topical composition is produced by the method comprising the steps of:

digesting a dermal biopsy specimen obtained from a human and comprising fibroblasts with a dissociative or digestive enzyme to form a fibroblast cell suspension, wherein the dermal biopsy specimen is from 1 to 5 mm in thickness, and between 4 and 12 cm 2 in area;

seeding the fibroblast cell suspension into a first tissue culture flask;

culturing the fibroblast cell suspension in the first tissue culture flask through at most three passages into a sequentially larger tissue culture flask;

harvesting the fibroblast conditioned medium from the fibroblast cell suspension during the culturing step, wherein the fibroblast cell suspension comprises 3×10 8 or more cells at harvest; and

formulating the conditioned medium into the topical composition.

2. The composition of claim 1 , wherein the fibroblast cell suspension is passaged twice.

3. The composition of claim 1 , wherein the fibroblast cell suspension is passaged once.

4. The composition of claim 1 , wherein the enzyme is a collagenase.

5. The composition of claim 4 , wherein the collagenase is liberase.

6. The composition of claim 1 , wherein the enzyme is trypsin.

7. The composition of claim 1 , wherein the first tissue culture flask is a T-125 flask, T-150 flask, T-175 flask, or T-225 flask.

8. The composition of claim 1 , wherein the sequentially larger tissue culture flask is a T-500 flask or multi-layer culture stack.

Assignments (8)
SECURITY INTEREST Recorded Mar 31, 2025
From: CASTLE CREEK BIOSCIENCES, LLC
To: LIGAND PHARMACEUTICALS INCORPORATED
Reel/Frame 070680/0695 →
SECURITY INTEREST Recorded Feb 25, 2025
From: CASTLE CREEK BIOSCIENCES, INC.
To: HORIZON TECHNOLOGY FINANCE CORPORATION
Reel/Frame 070317/0737 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2021
From: FIBROCELL TECHNOLOGIES, INC.
To: FIBROCELL SCIENCE, INC.
Reel/Frame 055641/0367 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2021
From: FIBROCELL SCIENCE, INC.
To: CASTLE CREEK BIOSCIENCES, LLC
Reel/Frame 055642/0372 →
CHANGE OF NAME Recorded Jun 23, 2016
From: ISOLAGEN, INC.
To: FIBROCELL SCIENCE, INC.
Reel/Frame 038993/0362 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2016
From: MASLOWSKI, JOHN
To: FIBROCELL SCIENCE, INC.
Reel/Frame 038993/0513 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2016
From: FIBROCELL SCIENCE, INC.
To: FIBROCELL TECHNOLOGIES, INC.
Reel/Frame 038993/0648 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 23, 2016
From: LINDNER, MARIE A.; THOMAS, MYRNA F.
To: ISOLAGEN, INC.
Reel/Frame 039132/0528 →
Continuity (3)
Continuation 12438932
Provisional Application 60823871 · Aug 29, 2006
Related Publication 20140335057A1 · Nov 13, 2014